The redox chemistry of the Alzheimer's disease amyloid β peptide

Biochimica et Biophysica Acta - Biomembranes

Volumn 1768, Issue 8, 2007, Pages 1976-1990

  Smith, Danielle G ^a,b,c   Cappai, Roberto ^a,b,c   Barnham, Kevin J ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Alzheimer's disease; Amyloid beta; Metal; Oxidative stress; Redox chemistry

Indexed keywords

1,1' XYLYL BIS 1,4,8,11 TETRAAZACYCLOTETRADECANE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; ASCORBIC ACID; CLIOQUINOL; COPPER; CURCUMIN; DEFEROXAMINE; GINKGO BILOBA EXTRACT; GOSSYPINE; IRON; JKL 169; MELATONIN; METALLOPROTEIN; METHIONINE; OLIGOMER; REACTIVE OXYGEN METABOLITE; TRIENTINE; TYROSINE; UNCLASSIFIED DRUG; ZINC;

ALZHEIMER DISEASE; BRAIN LEVEL; CLINICAL TRIAL; HUMAN; LIPID PEROXIDATION; MYELOOPTIC NEUROPATHY; NERVE DEGENERATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIOXIDANTS; CHELATING AGENTS; CURCUMIN; DNA; ENZYME INHIBITORS; GINKGO BILOBA; HUMANS; LIPID PEROXIDATION; METALS; OXIDATION-REDUCTION; OXYGEN; OXYGEN CONSUMPTION; PEPTIDES; PLANT EXTRACTS; REACTIVE OXYGEN SPECIES; TYROSINE;

EID: 34547147090     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2007.02.002     Document Type: Review

References (217)

1. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
2. Glenner G.G., and Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122 (1984) 1131-1135
3. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 4245-4249
4. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., and Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325 (1987) 733-736
5. Tanzi R.E., Gusella J.F., Watkins P.C., Bruns G.A., St George-Hyslop P., Van Keuren M.L., Patterson D., Pagan S., Kurnit D.M., and Neve R.L. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235 (1987) 880-884
6. Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U., and Gajdusek D.C. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 235 (1987) 877-880
7. Wasco W., Bupp K., Magendantz M., Gusella J.F., Tanzi R.E., and Solomon F. Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursor. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10758-10762
8. Slunt H.H., Thinakaran G., Von Koch C., Lo A.C., Tanzi R.E., and Sisodia S.S. Expression of a ubiquitous, cross-reactive homologue of the mouse beta-amyloid precursor protein (APP). J. Biol. Chem. 269 (1994) 2637-2644
9. Mattson M.P., Cheng B., Culwell A.R., Esch F.S., Lieberburg I., and Rydel R.E. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10 (1993) 243-254
10. Milward E.A., Papadopoulos R., Fuller S.J., Moir R.D., Small D., Beyreuther K., and Masters C.L. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 9 (1992) 129-137
11. Rossjohn J., Cappai R., Feil S.C., Henry A., McKinstry W.J., Galatis D., Hesse L., Multhaup G., Beyreuther K., Masters C.L., and Parker M.W. Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat. Struct. Biol. 6 (1999) 327-331
12. Saitoh T., Sundsmo M., Roch J.M., Kimura N., Cole G., Schubert D., Oltersdorf T., and Schenk D.B. Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. Cell 58 (1989) 615-622
13. Small D.H., Nurcombe V., Reed G., Clarris H., Moir R., Beyreuther K., and Masters C.L. A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J. Neurosci. 14 (1994) 2117-2127
14. Coulson E.J., Barrett G.L., Storey E., Bartlett P.F., Beyreuther K., and Masters C.L. Down-regulation of the amyloid protein precursor of Alzheimer's disease by antisense oligonucleotides reduces neuronal adhesion to specific substrata. Brain Res. 770 (1997) 72-80
15. Storey E., Beyreuther K., and Masters C.L. Alzheimer's disease amyloid precursor protein on the surface of cortical neurons in primary culture co-localizes with adhesion patch components. Brain Res. 735 (1996) 217-231
16. Storey E., Spurck T., Pickett-Heaps J., Beyreuther K., and Masters C.L. The amyloid precursor protein of Alzheimer's disease is found on the surface of static but not activity motile portions of neurites. Brain Res. 735 (1996) 59-66
17. Breen K.C., Bruce M., and Anderton B.H. Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion. J. Neurosci. Res. 28 (1991) 90-100
18. Gunawardena S., and Goldstein L.S. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 32 (2001) 389-401
19. Hesse L., Beher D., Masters C.L., and Multhaup G. The beta A4 amyloid precursor protein binding to copper. FEBS Lett. 349 (1994) 109-116
20. Multhaup G., Schlicksupp A., Hesse L., Beher D., Ruppert T., Masters C.L., and Beyreuther K. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science 271 (1996) 1406-1409
21. Barnham K.J., McKinstry W.J., Multhaup G., Galatis D., Morton C.J., Curtain C.C., Williamson N.A., White A.R., Hinds M.G., Norton R.S., Beyreuther K., Masters C.L., Parker M.W., and Cappai R. Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J. Biol. Chem. 278 (2003) 17401-17407
22. Multhaup G., Ruppert T., Schlicksupp A., Hesse L., Bill E., Pipkorn R., Masters C.L., and Beyreuther K. Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide. Biochemistry 37 (1998) 7224-7230
23. White A.R., Reyes R., Mercer J.F., Camakaris J., Zheng H., Bush A.I., Multhaup G., Beyreuther K., Masters C.L., and Cappai R. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 842 (1999) 439-444
24. Maynard C.J., Cappai R., Volitakis I., Cherny R.A., White A.R., Beyreuther K., Masters C.L., Bush A.I., and Li Q.X. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 277 (2002) 44670-44676
25. Bayer T.A., Schafer S., Simons A., Kemmling A., Kamer T., Tepest R., Eckert A., Schussel K., Eikenberg O., Sturchler-Pierrat C., Abramowski D., Staufenbiel M., and Multhaup G. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14187-14192
26. Phinney A.L., Drisaldi B., Schmidt S.D., Lugowski S., Coronado V., Liang Y., Horne P., Yang J., Sekoulidis J., Coomaraswamy J., Chishti M.A., Cox D.W., Mathews P.M., Nixon R.A., Carlson G.A., St George-Hyslop P., and Westaway D. In vivo reduction of amyloid-beta by a mutant copper transporter. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14193-14198
27. Halliwell B., and Gutterer J.M. Free Radicals in Biology and Medicine (1999), Oxford Univ. Press, Oxford
28. Arredondo M., and Nunez M.T. Iron and copper metabolism. Mol. Aspects Med. 26 (2005) 313-327
29. Floris G., and Agro A.F. Amine Oxidases. In: Lennarz W.J., and Lane M.D. (Eds). Encyclopedia of Biological Chemistry vol. 1 (2004), Elsevier Inc. 85-89
30. Martins R.N., Harper C.G., Stokes G.B., and Masters C.L. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J. Neurochem. 46 (1986) 1042-1045
31. Balazs L., and Leon M. Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem. Res. 19 (1994) 1131-1137
32. Schipper H.M. Heme oxygenase expression in human central nervous system disorders. Free Radic. Biol. Med. 37 (2004) 1995-2011
33. Markesbery W.R., and Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 19 (1998) 33-36
34. Sayre L.M., Zelasko D.A., Harris P.L., Perry G., Salomon R.G., and Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68 (1997) 2092-2097
35. Williams T.I., Lynn B.C., Markesbery W.R., and Lovell M.A. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol. Aging 27 (2006) 1094-1099
36. Montine K.S., Kim P.J., Olson S.J., Markesbery W.R., and Montine T.J. 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J. Neuropathol. Exp. Neurol. 56 (1997) 866-871
37. Ando Y., Brannstrom T., Uchida K., Nyhlin N., Nasman B., Suhr O., Yamashita T., Olsson T., El Salhy M., Uchino M., and Ando M. Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J. Neurol. Sci. 156 (1998) 172-176
38. Stadtman E.R., and Berlett B.S. Reactive oxygen-mediated protein oxidation in aging and disease. Chem. Res. Toxicol. 10 (1997) 485-494
39. Nitsch R.M., Blusztajn J.K., Pittas A.G., Slack B.E., Growdon J.H., and Wurtman R.J. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 1671-1675
40. Pamplona R., Dalfo E., Ayala V., Bellmunt M.J., Prat J., Ferrer I., and Portero-Otin M. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J. Biol. Chem. 280 (2005) 21522-21530
41. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65 (1995) 2146-2156
42. Butterfield D.A., Yatin S.M., and Link C.D. In vitro and in vivo protein oxidation induced by Alzheimer's disease amyloid beta-peptide (1-42). Ann. N. Y. Acad. Sci. 893 (1999) 265-268
43. Aksenova M.V., Aksenov M.Y., Payne R.M., Trojanowski J.Q., Schmidt M.L., Carney J.M., Butterfield D.A., and Markesbery W.R. Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders. Dement. Geriatr. Cogn. Disord. 10 (1999) 158-165
44. Aksenov M.Y., Aksenova M.V., Butterfield D.A., Geddes J.W., and Markesbery W.R. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103 (2001) 373-383
45. Lyras L., Cairns N.J., Jenner A., Jenner P., and Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 68 (1997) 2061-2069
46. Hensley K., Maidt M.L., Yu Z., Sang H., Markesbery W.R., and Floyd R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 18 (1998) 8126-8132
47. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17 (1997) 2653-2657
48. Huggins T.G., Staton M.W., Dyer D.G., Detorie N.J., Walla M.D., Baynes J.W., and Thorpe S.R. o-Tyrosine and dityrosine concentrations in oxidized proteins and lens proteins with age. Ann. N. Y. Acad. Sci. 663 (1992) 436-437
49. Leeuwenburgh C., Hansen P.A., Holloszy J.O., and Heinecke J.W. Hydroxyl radical generation during exercise increases mitochondrial protein oxidation and levels of urinary dityrosine. Free Radic. Biol. Med. 27 (1999) 186-192
50. Leeuwenburgh C., Hansen P.A., Holloszy J.O., and Heinecke J.W. Oxidized amino acids in the urine of aging rats: potential markers for assessing oxidative stress in vivo. Am. J. Physiol. 276 (1999) R128-R135
51. Head E., Lott I.T., Cribbs D.H., Cotman C.W., and Rohn T.T. Beta-amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome. Neurosci. Lett. 330 (2002) 99-103
52. Dong J., Atwood C.S., Anderson V.E., Siedlak S.L., Smith M.A., Perry G., and Carey P.R. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42 (2003) 2768-2773
53. Lovell M.A., Xie C., Gabbita S.P., and Markesbery W.R. Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic. Biol. Med. 28 (2000) 418-427
54. Lovell M.A., Xie C., and Markesbery W.R. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51 (1998) 1562-1566
55. Volkel W., Sicilia T., Pahler A., Gsell W., Tatschner T., Jellinger K., Leblhuber F., Riederer P., Lutz W.K., and Gotz M.E. Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease. Neurochem. Int. 48 (2006) 679-686
56. Marcus D.L., Strafaci J.A., and Freedman M.L. Differential neuronal expression of manganese superoxide dismutase in Alzheimer's disease. Med. Sci. Monit. 12 (2006) BR8-BR14
57. Snaedal J., Kristinsson J., Gunnarsdottir S., Ólafsdóttir Á., Baldvinsson M., and Johannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. a case-control study. Dement. Geriatr. Cogn. Disord. 9 (1998) 239-242
58. De Leo M.E., Borrello S., Passantino M., Palazzotti B., Mordente A., Daniele A., Filippini V., Galeotti T., and Masullo C. Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease. Neurosci. Lett. 250 (1998) 173-176
59. Zemlan F.P., Thienhaus O.J., and Bosmann H.B. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. Brain Res. 476 (1989) 160-162
60. Perrin R., Briancon S., Jeandel C., Artur Y., Minn A., Penin F., and Siest G. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: a case-control study. Gerontology 36 (1990) 306-313
61. Ramassamy C., Averill D., Beffert U., Bastianetto S., Theroux L., Lussier-Cacan S., Cohn J.S., Christen Y., Davignon J., Quirion R., and Poirier J. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic. Biol. Med. 27 (1999) 544-553
62. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., Norton M.C., Welsh-Bohmer K.A., and Breitner J.C. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 61 (2004) 82-88
63. Bush A.I. The metallobiology of Alzheimer's disease. Trends Neurosci. 26 (2003) 207-214
64. Opazo C., Huang X., Cherny R.A., Moir R.D., Roher A.E., White A.R., Cappai R., Masters C.L., Tanzi R.E., Inestrosa N.C., and Bush A.I. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 277 (2002) 40302-40308
65. Hartter D.E., and Barnea A. Brain tissue accumulates 67copper by two ligand-dependent saturable processes. A high affinity, low capacity and a low affinity, high capacity process. J. Biol. Chem. 263 (1988) 799-805
66. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., and Markesbery W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158 (1998) 47-52
67. Gutteridge J.M. Copper-phenanthroline-induced site-specific oxygen-radical damage to DNA. Detection of loosely bound trace copper in biological fluids. Biochem. J. 218 (1984) 983-985
68. Kardos J., Kovacs I., Hajos F., Kalman M., and Simonyi M. Nerve endings from rat brain tissue release copper upon depolarization. A possible role in regulating neuronal excitability. Neurosci. Lett. 103 (1989) 139-144
69. Linder M.C., and Hazegh-Azam M. Copper biochemistry and molecular biology. Am. J. Clin. Nutr. 63 (1996) 797S-811S
70. Schumann K., Classen H.G., Dieter H.H., Konig J., Multhaup G., Rukgauer M., Summer K.H., Bernhardt J., and Biesalski H.K. Hohenheim consensus workshop: copper. Eur. J. Clin. Nutr. 56 (2002) 469-483
71. Stuerenburg H.J. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease. J. Neural Transm. 107 (2000) 321-329
72. White A.R., Barnham K.J., Huang X., Voltakis I., Beyreuther K., Masters C.L., Cherny R.A., Bush A.I., and Cappai R. Iron inhibits neurotoxicity induced by trace copper and biological reductants. J. Biol. Inorg. Chem. 9 (2004) 269-280
73. Tandon L., Ni B.-F., Ding X.X., Ehmann W.D., Kasarskis E.J., and Markesbery W.R. RNAA for arsenic, cadium, copper and molybdenum in CNS tissues from subjects with age-related neurodegenerative disease. J. Radioanal. Nucl. Chem. 179 (1994) 331-339
74. Ward N.I., and Mason J.A. Neutron activation analysis techniques for identifying elemental status in Alzheimer's disease. J. Radioanal. Nucl. Chem. 113 (1987) 515-526
75. Plantin L.-O., Lysing-Tunell U., and Kristensson K. Trace elements in the human central nervous system studied with neutron activation analysis. Biol. Trace Elem. Res. 1987 (1987) 69-75
76. Deibel M.A., Ehmann W.D., and Markesbery W.R. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J. Neurol. Sci. 143 (1996) 137-142
77. Lee J.Y., Mook-Jung I., and Koh J.Y. Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J. Neurosci. 19 (1999) RC10
78. Hershey C.O., Hershey L.A., Varnes A., Vibhakar S.D., Lavin P., and Strain W.H. Cerebrospinal fluid trace element content in dementia: clinical, radiologic, and pathologic correlations. Neurology 33 (1983) 1350-1353
79. Corrigan F.M., Reynolds G.P., and Ward N.I. Hippocampal tin, aluminum and zinc in Alzheimer's disease. Biometals 6 (1993) 149-154
80. Diebel M., Ehrmann W., and Markesbery W.R. Copper, Iron and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J. Neurol. Sci. 143 (1996) 137-142
81. Bush A.I. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging 23 (2002) 1031-1038
82. Frederickson C.J. Neurobiology of zinc and zinc-containing neurons. Int. Rev. Neurobiol. 31 (1989) 145-238
83. Assaf S.Y., and Chung S.H. Release of endogenous Zn2+ from brain tissue during activity. Nature 308 (1984) 734-736
84. Howell G.A., Welch M.G., and Frederickson C.J. Stimulation-induced uptake and release of zinc in hippocampal slices. Nature 308 (1984) 736-738
85. Cuajungco M.P., Goldstein L.E., Nunomura A., Smith M.A., Lim J.T., Atwood C.S., Huang X., Farrag Y.W., Perry G., and Bush A.I. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J. Biol. Chem. 275 (2000) 19439-19442
86. Lovell M.A., Xie C., and Markesbery W.R. Protection against amyloid beta peptide toxicity by zinc. Brain Res. 823 (1999) 88-95
87. Fuson K.S., Boggs L.N., and May P.C. Zonc promotes Abeta aggregation but attenuates Abeta neurotoxicity. Neurobiol. Aging 17 (1996) 431
88. Yoshiike Y., Tanemura K., Murayama O., Akagi T., Murayama M., Sato S., Sun X., Tanaka N., and Takashima A. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J. Biol. Chem. 276 (2001) 32293-32299
89. Cardoso S.M., Rego A.C., Pereira C., and Oliveira C.R. Protective effect of zinc on amyloid?-beta ?25-35 and 1-40? mediated toxicity. Neurotox. Res. 7 (2005) 273-282
90. Bhatia R., Lin H., and Lal R. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. FASEB J. 14 (2000) 1233-1243
91. Hirakura Y., Yiu W.W., Yamamoto A., and Kagan B.L. Amyloid peptide channels: blockade by zinc and inhibition by Congo red (amyloid channel block). Amyloid 7 (2000) 194-199
92. Lin H., Zhu Y.J., and Lal R. Amyloid beta protein (1-40) forms calcium-permeable, Zn2+-sensitive channel in reconstituted lipid vesicles. Biochemistry 38 (1999) 11189-11196
93. Rhee S.K., Quist A.P., and Lal R. Amyloid beta protein-(1-42) forms calcium-permeable, Zn2+-sensitive channel. J. Biol. Chem. 273 (1998) 13379-13382
94. Zhu Y.J., Lin H., and Lal R. Fresh and nonfibrillar amyloid beta protein (1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for AbetaP-channel-mediated cellular toxicity. FASEB J. 14 (2000) 1244-1254
95. Arispe N., Pollard H.B., and Rojas E. Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1710-1715
96. Kawahara M., Arispe N., Kuroda Y., and Rojas E. Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophys. J. 73 (1997) 67-75
97. Huang X., Atwood C.S., Moir R.D., Hartshorn M.A., Vonsattel J.P., Tanzi R.E., and Bush A.I. Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J. Biol. Chem. 272 (1997) 26464-26470
98. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E., Scarpa R.C., Saunders A.J., Lim J., Moir R.D., Glabe C., Bowden E.F., Masters C.L., Fairlie D.P., Tanzi R.E., and Bush A.I. Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274 (1999) 37111-37116
99. Tudor R., Zalewski P.D., and Ratnaike R.N. Zinc in health and chronic disease. J. Nutr. Health Aging 9 (2005) 45-51
100. Potocnik F.C., van Rensburg S.J., Park C., Taljaard J.J., and Emsley R.A. Zinc and platelet membrane microviscosity in Alzheimer's disease. The in vivo effect of zinc on platelet membranes and cognition. S. Afr. Med. J. 87 (1997) 1116-1119
101. Van Rhijin A.G., Prior C.A., and Corrigan F.M. Dietary Supplementation with zinc sulphate, sodium selenite and fatty acids in early dementia of Alzheimer's type. J. Nutr. Med. 1 (1990) 259-266
102. Ehmann W.D., Markesbery W.R., Alauddin M., Hossain T.I.M., and Brubaker E.H. Brain Trace elements in Alzheimer's disease. Neurotoxicology 7 (1986) 197-206
103. Thompson C.M., Markesbery W.R., Ehmann W.D., Mao Y.X., and Vance D.E. Regional brain trace element studies in Alzheimer's disease. Neurotoxicology 9 (1988) 1-8
104. Rottkamp C.A., Raina A.K., Zhu X., Gaier E., Bush A.I., Atwood C.S., Chevion M., Perry G., and Smith M.A. Redox-active iron mediates amyloid-beta toxicity. Free Radic. Biol. Med. 30 (2001) 447-450
105. Khan A., Dobson J.P., and Exley C. Redox cycling of iron by Abeta42. Free Radic. Biol. Med. 40 (2006) 557-569
106. Hu W.P., Chang G.L., Chen S.J., and Kuo Y.M. Kinetic analysis of beta-amyloid peptide aggregation induced by metal ions based on surface plasmon resonance biosensing. J. Neurosci. Methods 154 (2006) 190-197
107. Grundke-Iqbal I., Fleming J., Tung Y.C., Lassmann H., Iqbal K., and Joshi J.G. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol. (Berl.) 81 (1990) 105-110
108. Swtizer R.C., Martin T.L., Campbell S.K., Parker J.C., and Caldwell E.D. Iron and ferritin in the neuritic plaques of Alzheimer's disease. Abstr. - Soc. Neurosci. 100 (1986)
109. Connor J.R., Snyder B.S., Beard J.L., Fine R.E., and Mufson E.J. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 31 (1992) 327-335
110. Connor J.R., Menzies S.L., St Martin S.M., and Mufson E.J. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J. Neurosci. Res. 31 (1992) 75-83
111. Connor J.R., and Menzies S.L. Cellular management of iron in the brain. J. Neurol. Sci. 134 (1995) 33-44 (Suppl.)
112. Atamna H., and Frey II W.H. A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11153-11158
113. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
114. Smith M.A., Wehr K., Harris P.L., Siedlak S.L., Connor J.R., and Perry G. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res. 788 (1998) 232-236
115. Lee J.Y., Cole T.B., Palmiter R.D., Suh S.W., and Koh J.Y. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7705-7710
116. Flood J.F., and Morley J.E. Age-related changes in footshock avoidance acquisition and retention in senescence accelerated mouse (SAM). Neurobiol. Aging 14 (1993) 153-157
117. Poon H.F., Joshi G., Sultana R., Farr S.A., Banks W.A., Morley J.E., Calabrese V., and Butterfield D.A. Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Res. 1018 (2004) 86-96
118. Atwood C.S., Scarpa R.C., Huang X., Moir R.D., Jones W.D., Fairlie D.P., Tanzi R.E., and Bush A.I. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 75 (2000) 1219-1233
119. Curtain C.C., Ali F., Volitakis I., Cherny R.A., Norton R.S., Beyreuther K., Barrow C.J., Masters C.L., Bush A.I., and Barnham K.J. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276 (2001) 20466-20473
120. Karr J.W., Akintoye H., Kaupp L.J., and Szalai V.A. N-terminal deletions modify the Cu2+ binding site in amyloid-beta. Biochemistry 44 (2005) 5478-5487
121. Syme C.D., Nadal R.C., Rigby S.E., and Viles J.H. Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Abeta-(1-28): insights from a range of complementary spectroscopic techniques. J. Biol. Chem. 279 (2004) 18169-18177
122. Miura T., Suzuki K., Kohata N., and Takeuchi H. Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry 39 (2000) 7024-7031
123. Boyd-Kimball D., Sultana R., Mohmmad-Abdul H., and Butterfield D.A. Rodent Abeta(1-42) exhibits oxidative stress properties similar to those of human Abeta(1-42): Implications for proposed mechanisms of toxicity. J. Alzheimer's Dis. 6 (2004) 515-525
124. Kanski J., Aksenova M., Schoneich C., and Butterfield D.A. Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide. Free Radic. Biol. Med. 32 (2002) 1205-1211
125. Butterfield D.A., and Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Peptides 23 (2002) 1299-1309
126. Yatin S.M., Varadarajan S., Link C.D., and Butterfield D.A. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol. Aging 20 (1999) 325-330 discussion 339-342
127. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radical Res. 36 (2002) 1307-1313
128. Butterfield D.A., and Bush A.I. Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol. Aging 25 (2004) 563-568
129. Butterfield D.A., Griffin S., Munch G., and Pasinetti G.M. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J. Alzheimers Dis. 4 (2002) 193-201
130. Varadarajan S., Kanski J., Aksenova M., Lauderback C., and Butterfield D.A. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1-42) and A beta(25-35). J. Am. Chem. Soc. 123 (2001) 5625-5631
131. Schubert D., and Chevion M. The role of iron in beta amyloid toxicity. Biochem. Biophys. Res. Commun. 216 (1995) 702-707
132. Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E., and Bush A.I. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38 (1999) 7609-7616
133. Turnbull S., Tabner B.J., El-Agnaf O.M., Twyman L.J., and Allsop D. New evidence that the Alzheimer beta-amyloid peptide does not spontaneously form free radicals: an ESR study using a series of spin-traps. Free Radic. Biol. Med. 30 (2001) 1154-1162
134. Barnham K.J., Ciccotosto G.D., Tickler A.K., Ali F.E., Smith D.G., Williamson N.A., Lam Y.H., Carrington D., Tew D., Kocak G., Volitakis I., Separovic F., Barrow C.J., Wade J.D., Masters C.L., Cherny R.A., Curtain C.C., Bush A.I., and Cappai R. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 278 (2003) 42959-42965
135. Barnham K.J., Haeffner F., Ciccotosto G.D., Curtain C.C., Tew D., Mavros C., Beyreuther K., Carrington D., Masters C.L., Cherny R.A., Cappai R., and Bush A.I. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J. 18 (2004) 1427-1429
136. Bruce A.J., Malfroy B., and Baudry M. beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2312-2316
137. Behl C., Davis J.B., Lesley R., and Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77 (1994) 817-827
138. Milton N.G. Amyloid-beta binds catalase with high affinity and inhibits hydrogen peroxide breakdown. Biochem. J. 344 Pt 2 (1999) 293-296
139. Ciccotosto G.D., Tew D., Curtain C.C., Smith D., Carrington D., Masters C.L., Bush A.I., Cherny R.A., Cappai R., and Barnham K.J. Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J. Biol. Chem. 279 (2004) 42528-42534
140. Tabner B.J., Turnbull S., El-Agnaf O.M., and Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic. Biol. Med. 32 (2002) 1076-1083
141. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23 (1997) 134-147
142. Liochev S.I. The mechanism of "Fenton-like" reactions and their importance for biological systems. A biologist's view. Met. Ions Biol. Syst. 36 (1999) 1-39
143. Ali F.E., Separovic F., Barrow C.J., Cherny R.A., Fraser F., Bush A.I., Masters C.L., and Barnham K.J. Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. J. Pept. Sci. 11 (2005) 353-360
144. Schiewe A.J., Margol L., Soreghan B.A., Thomas S.N., and Yang A.J. Rapid characterization of amyloid-beta side-chain oxidation by tandem mass spectrometry and the scoring algorithm for spectral analysis. Pharm. Res. 21 (2004) 1094-1102
145. Clementi M.E., Marini S., Coletta M., Orsini F., Giardina B., and Misiti F. Abeta(31-35) and Abeta(25-35) fragments of amyloid beta-protein induce cellular death through apoptotic signals: Role of the redox state of methionine-35. FEBS Lett. 579 (2005) 2913-2918
146. Misiti F., Martorana G.E., Nocca G., Di Stasio E., Giardina B., and Clementi M.E. Methionine 35 oxidation reduces toxic and pro-apoptotic effects of the amyloid beta-protein fragment (31-35) on isolated brain mitochondria. Neuroscience 126 (2004) 297-303
147. Kanski J., Varadarajan S., Aksenova M., and Butterfield D.A. Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-peptide 1-42-associated oxidative stress and neurotoxicity. Biochim. Biophys. Acta 1586 (2002) 190-198
148. Pogocki D., and Schoneich C. Redox properties of Met(35) in neurotoxic beta-amyloid peptide. A molecular modelling study. Chem. Res. Toxicol. 15 (2002) 408-418
149. Naslund J., Schierhorn A., Hellman U., Lannfelt L., Roses A.D., Tjernberg L.O., Silberring J., Gandy S.E., Winblad B., Greengard P., et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8378-8382
150. Kuo Y.M., Kokjohn T.A., Beach T.G., Sue L.I., Brune D., Lopez J.C., Kalback W.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., and Roher A.E. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 276 (2001) 12991-12998
151. Singh V.K., Cheng J.F., and Leu S.J. Effect of substance P and protein kinase inhibitors on beta-amyloid peptide-induced proliferation of cultured brain cells. Brain Res. 660 (1994) 353-356
152. Stephenson D.T., and Clemens J.A. In vivo effects of beta-amyloid implants in rodents: lack of potentiation of damage associated with transient global forebrain ischemia. Brain Res. 586 (1992) 235-246
153. Takenouchi T., and Munekata E. beta-Amyloid peptide, substance P, and SEC receptor ligand activate cytoplasmic Ca2+ in neutrophil-like HL-60 cells: effect of chemotactic peptide antagonist BocMLF. Peptides 16 (1995) 1019-1024
154. Whitson J.S., Glabe C.G., Shintani E., Abcar A., and Cotman C.W. Beta-amyloid protein promotes neuritic branching in hippocampal cultures. Neurosci. Lett. 110 (1990) 319-324
155. Whitson J.S., Selkoe D.J., and Cotman C.W. Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science 243 (1989) 1488-1490
156. Yankner B.A., Duffy L.K., and Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250 (1990) 279-282
157. Simmons M.A., and Schneider C.R. Amyloid beta peptides act directly on single neurons. Neurosci. Lett. 150 (1993) 133-136
158. Ueda K., Fukui Y., and Kageyama H. Amyloid beta protein-induced neuronal cell death: neurotoxic properties of aggregated amyloid beta protein. Brain Res. 639 (1994) 240-244
159. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6448-6453
160. Pike C.J., Walencewicz A.J., Glabe C.G., and Cotman C.W. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur. J. Pharmacol. 207 (1991) 367-368
161. Behl C., Davis J.B., Klier F.G., and Schubert D. Amyloid beta peptide induces necrosis rather than apoptosis. Brain Res. 645 (1994) 253-264
162. Lee H.G., Castellani R.J., Zhu X., Perry G., and Smith M.A. Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?. Int. J. Exp. Pathol. 86 (2005) 133-138
163. Kontush A., Berndt C., Weber W., Akopyan V., Arlt S., Schippling S., and Beisiegel U. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic. Biol. Med. 30 (2001) 119-128
164. Chan C.-W., Dharmarajan A., Atwood C.S., Huang X., Tanzi R.E., Bush A.I., and Martins R.N. Anti-apoptotic action of Alzheimer Abeta. Alzheimer's Rep. 2 (1999) 1-6
165. Wang J., Dickson D.W., Trojanowski J.Q., and Lee V.M. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158 (1999) 328-337
166. Koppal T., Subramaniam R., Drake J., Prasad M.R., Dhillon H., and Butterfield D.A. Vitamin E protects against Alzheimer's amyloid peptide (25-35)-induced changes in neocortical synaptosomal membrane lipid structure and composition. Brain Res. 786 (1998) 270-273
167. Vogt W. Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic. Biol. Med. 18 (1995) 93-105
168. Kadlcik V., Sicard-Roselli C., Mattioli T.A., Kodicek M., and Houee-Levin C. One-electron oxidation of beta-amyloid peptide: sequence modulation of reactivity. Free Radic. Biol. Med. 37 (2004) 881-891
169. Varadarajan S., Yatin S., Kanski J., Jahanshahi F., and Butterfield D.A. Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress. Brain Res. Bull. 50 (1999) 133-141
170. Page C.C., Moser C.C., Chen X., and Dutton P.L. Natural engineering principles of electron tunnelling in biological oxidation-reduction. Nature 402 (1999) 47-52
171. Rauk A., Armstrong D.A., and Fairlie D.P. Is oxidative damage mediated by amyoid beta and prion peptide mediated by hydrogen atom transfer from glycine alpha-carbon to methionine sulfur within beta-sheets?. J. Am. Chem. Soc. 122 (2000) 9761-9767
172. Lovell M.A., Ehmann W.D., Mattson M.P., and Markesbery W.R. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol. Aging 18 (1997) 457-461
173. Esterbauer H., Schaur R.J., and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11 (1991) 81-128
174. Spiteller G. Peroxyl radicals: inductors of neurodegenerative and other inflammatory diseases. Their origin and how they transform cholesterol, phospholipids, plasmalogens, polyunsaturated fatty acids, sugars, and proteins into deleterious products. Free Radic. Biol. Med. 41 (2006) 362-387
175. Palmblad M., Westlind-Danielsson A., and Bergquist J. Oxidation of methionine 35 attenuates formation of amyloid beta -peptide 1-40 oligomers. J. Biol. Chem. 277 (2002) 19506-19510
176. Ali F.E., Barnham K.J., Barrow C.J., and Separovic F. Metal catalyzed oxidation of tyrosine residues by different oxidation systems of copper/hydrogen peroxide. J. Inorg. Biochem. 98 (2004) 173-184
177. Atwood C.S., Huang X., Khatri A., Scarpa R.C., Kim Y.S., Moir R.D., Tanzi R.E., Roher A.E., and Bush A.I. Copper catalyzed oxidation of Alzheimer Abeta. Cell Mol. Biol. (Noisy-le-grand) 46 (2000) 777-783
178. Onorato J.M., Thorpe S.R., and Baynes J.W. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann. N. Y. Acad. Sci. 854 (1998) 277-290
179. Atwood C.S., Perry G., Zeng H., Kato Y., Jones W.D., Ling K.Q., Huang X., Moir R.D., Wang D., Sayre L.M., Smith M.A., Chen S.G., and Bush A.I. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 43 (2004) 560-568
180. Metodiewa D. Molecular mechanisms of cellular injury produced by neurotoxic amino acids that generate reactive oxygen species. Amino Acids 14 (1998) 181-187
181. Pennathur S., Jackson-Lewis V., Przedborski S., and Heinecke J.W. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem. 274 (1999) 34621-34628
182. Malencik D.A., and Anderson S.R. Dityrosine as a product of oxidative stress and fluorescent probe. Amino Acids 25 (2003) 233-247
183. Kuo Y.M., Emmerling M.R., Vigo-Pelfrey C., Kasunic T.C., Kirkpatrick J.B., Murdoch G.H., Ball M.J., and Roher A.E. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271 (1996) 4077-4081
184. Roher A.E., Chaney M.O., Kuo Y.M., Webster S.D., Stine W.B., Haverkamp L.J., Woods A.S., Cotter R.J., Tuohy J.M., Krafft G.A., Bonnell B.S., and Emmerling M.R. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271 (1996) 20631-20635
185. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
186. Yoon I., Lee K.H., and Cho J. Gossypin protects primary cultured rat cortical cells from oxidative stress- and beta-amyloid-induced toxicity. Arch. Pharm. Res. 27 (2004) 454-459
187. Zatta P., Tognon G., and Carampin P. Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)]. J. Pineal. Res. 35 (2003) 98-103
188. Feng Z., Chang Y., Cheng Y., Zhang B.L., Qu Z.W., Qin C., and Zhang J.T. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J. Pineal. Res. 37 (2004) 129-136
189. Matsubara E., Bryant-Thomas T., Pacheco Quinto J., Henry T.L., Poeggeler B., Herbert D., Cruz-Sanchez F., Chyan Y.J., Smith M.A., Perry G., Shoji M., Abe K., Leone A., Grundke-Ikbal I., Wilson G.L., Ghiso J., Williams C., Refolo L.M., Pappolla M.A., Chain D.G., and Neria E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem. 85 (2003) 1101-1108
190. Cheng Y., Feng Z., Zhang Q.Z., and Zhang J.T. Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol. Sin. 27 (2006) 129-139
191. Defeudis F.V. Bilobalide and neuroprotection. Pharmacol. Res. 46 (2002) 565-568
192. Oken B.S., Storzbach D.M., and Kaye J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol. 55 (1998) 1409-1415
193. Le Bars P.L. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. Pharmacopsychiatry 36 Suppl. 1 (2003) S50-S55
194. Schneider L.S., DeKosky S.T., Farlow M.R., Tariot P.N., Hoerr R., and Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr. Alzheimer Res. 2 (2005) 541-551
195. Yao Z., and Papadopoulos Drieu.V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 889 (2001) 181-190
196. Kelloff G.J., Crowell J.A., Steele V.E., Lubet R.A., Malone W.A., Boone C.W., Kopelovich L., Hawk E.T., Lieberman R., Lawrence J.A., Ali I., Viner J.L., and Sigman C.C. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J. Nutr. 130 (2000) 467S-471S
197. Ganguli M., Chandra V., Kamboh M.I., Johnston J.M., Dodge H.H., Thelma B.K., Juyal R.C., Pandav R., Belle S.H., and DeKosky S.T. Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch. Neurol. 57 (2000) 824-830
198. Shishodia S., Sethi G., and Aggarwal B.B. Curcumin: getting back to the roots. Ann. N. Y. Acad. Sci. 1056 (2005) 206-217
199. Aksenov M.Y., and Markesbery W.R. Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease. Neurosci. Lett. 302 (2001) 141-145
200. Ringman J.M., Frautschy S.A., Cole G.M., Masterman D.L., and Cummings J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer Res. 2 (2005) 131-136
201. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., and Cole G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280 (2005) 5892-5901
202. Baum L., and Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis. 6 (2004) 367-377 (discussion 443-369)
203. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. N. Y. Acad. Sci. 119 (1964) 758-768
204. Cuajungco M.P., Faget K.Y., Huang X., Tanzi R.E., and Bush A.I. Metal chelation as a potential therapy for Alzheimer's disease. Ann. N. Y. Acad. Sci. 920 (2000) 292-304
205. Walton J.R. Aluminum in hippocampal neurons from humans with Alzheimer's disease. Neurotoxicology 27 (2006) 385-394
206. Perry E.K., and Perry R.H. New insights into the nature of senile (Alzheimer-type) plaques. Trends Neurosci. 8 (1985) 301-303
207. Perl D.P., and Brody A.R. Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 208 (1980) 297-299
208. Lovell M.A., Ehmann W.D., and Markesbery W.R. Laser microprobe analysis of brain aluminum in Alzheimer's disease. Ann. Neurol. 33 (1993) 36-42
209. Kawahara M. Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. J. Alzheimers Dis. 8 (2005) 171-182 (discussion 209-115)
210. Moret V., Laras Y., Pietrancosta N., Garino C., Quelever G., Rolland A., Mallet B., Norreel J.C., and Kraus J.L. 1,1′-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorg. Med. Chem. Lett. 16 (2006) 3298-3301
211. Lee J.Y., Friedman J.E., Angel I., Kozak A., and Koh J.Y. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol. Aging 25 (2004) 1315-1321
212. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., and Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
213. Perluigi M., Joshi G., Sultana R., Calabrese V., De Marco C., Coccia R., and Butterfield D.A. In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1-42)-induced oxidative stress. Neuroscience 138 (2006) 1161-1170
214. Nakae S., Iwa T., Asai Y., Anjiki H., and Kameta Y. [Long-term follow-up following anastomosis of the superior vena cava and pulmonary artery]. Nippon Kyobu Geka Gakkai Zasshi 21 (1973) 530-537
215. Yassin M.S., Ekblom J., Xilinas M., Gottfries C.G., and Oreland L. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J. Neurol. Sci. 173 (2000) 40-44
216. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., and Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60 (2003) 1685-1691
217. Reinhard C., Hebert S.S., and De Strooper B. The amyloid-beta precursor protein: integrating structure with biological function. EMBO J. 24 (2005) 3996-4006